Thetis receives funding for IBD therapy

Thetis Pharmaceuticals has received funding from the Crohn’s & Colitis Foundation’s IBD Ventures program to support development of TP-317, a first-in-class, oral therapy for inflammatory bowel disease.

The active agent in TP-317 is Resolvin E1, an endogenous immuno-resolvent.  “Resolvin E1 is a potent bioactive lipid mediator produced locally in inflamed tissue to orchestrate resolution of inflammation, reduction of pain and tissue repair following initiation of an acute inflammatory response,” stated Dr. Serhan, a scientific advisor to Thetis. more